CRISPR Therapeutics, model coverage complete at +3.6% since entry

CRISPR Therapeutics is in week 11 of a buy signal, with the trade up 3.6% since entry. All 3 targets of our most advanced model have already been hit and model coverage is complete: residual capital now carries on, with a dynamic stop tighter than the structural level. Signal strength stays medium-weak, in a context of elevated volatility.